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Background: Quantifying antibiotic use is an essential element of antibiotic stewardship since it allows compari-
son between different settings and time windows, and measurement of the impact of interventions. However,
quantity metrics (QMs) and methods have not been standardized.
Objectives: To propose a set of QMs for antibiotic use in inpatients (IQMs) that are accepted globally by profes-
sionals in a range of disciplines. The study was conducted within the Driving Reinvestment in Research and
Development and Responsible Antibiotic Use (DRIVE-AB) project.
Methods: A systematic literature review using MEDLINE identified articles on measuring inpatient antibiotic use,
published up to 29 January 2015. A consensually selected list of national and international web sites was
screened for additional IQMs. IQMs were classified according to the type of numerator used and presented to a
multidisciplinary panel of stakeholders. A RAND-modified Delphi consensus procedure, which consisted of two
online questionnaires and a face-to-face meeting, was performed.
Results: The systematic literature review and web site search identified 168 eligible articles from which an initial
list of 20 IQMs, composed of 20 different numerators and associated denominators was developed. The consen-
sus procedure resulted in a final set of 12 IQMs. Among this final set, DDDs per 100(0) patient-days and days of
therapy per patient-days were most frequently found in the review. The panel recommended that antibiotic use
should be expressed in at least two metrics simultaneously.
Conclusions: Our consensus procedure identified a set of IQMs that we propose as an evidence-based global
standard.
Introduction
Introduction of antibiotic treatment, together with hygiene meas-
ures, was probably one of the main causes for the notable reduc-
tion in morbidity and mortality rates caused by bacterial infections
in the last century.1 However, infections with bacteria resistant to
many commonly used antimicrobials are one of the major treat-
ment challenges nowadays.2 The development of new antibiotics
and the responsible use of existing ones represent valuable options
to combat the spread and emergence of antimicrobial resistance.
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Since the development of new antibiotics is a difficult endeavour
due to scientific complexity, and financial, time and safety issues,
responsible use of existing antibiotics remains crucial to preserve
their effectiveness.3
Measuring the quantity of antibiotic use is one of the key strat-
egies in antimicrobial stewardship programmes since measure-
ment of antibiotic use is the first step that leads to control and
eventually to an improvement of use.4 Quantity metrics may
reflect the volume or costs of antibiotic use and proper comparison
of antibiotic consumption is enabled only by standardization of its
quantification.4 Zanichelli et al.5 showed a large variation in quanti-
tative metrics for antibiotic use across similar settings and pro-
viders and for specific medical conditions and populations, both in
high- and low- to middle-income countries. Reducing antimicrobial
resistance through responsible antibiotic use and identifying how
to incentivize the discovery and development of novel antibiotics
through new economic models are the most important goals of
the Driving Reinvestment in Research and Development and
Responsible Antibiotic Use (DRIVE-AB) project, funded by the
Innovative Medicines Initiative.6,7
This study, which is part of the DRIVE-AB project, aimed to
develop a set of evidence-based and consensually validated quan-
tity metrics for antibiotic use for the inpatient setting. Additionally,
inpatient quality indicators are presented by Monnier et al.8
Materials and methods
Systematic review of the literature
A systematic literature review, followed by a RAND-modified Delphi consen-
sus procedure, was performed according to previously described
methods.9–11 This review is reported according to the PRISMA statement.12
The MEDLINE (via the PubMed interface) electronic database from
inception until 29 January 2015 was searched. The search strategy was
built using the combination of four main search term concepts: (i) antibiot-
ics; (ii) quantity/utilization; (iii) measurement unit; and (iv) inpatient
(a detailed list of search terms is provided in Table S1, available as
Supplementary data at JAC Online). In addition, the reference lists of
included articles identified by the literature search were hand-searched to
identify any additional relevant studies.
Inclusion and exclusion criteria
Articles were included if they were written in English, concerned systemic
(i.e. not topical, vaginal or inhaled) antibiotic use in humans and reported
quantity metrics for antibiotic use/prescribing in the hospital setting. Papers
on antiviral, antifungal and antiparasitic drugs were excluded, as well as
articles describing antibiotic use in tuberculosis and in pathologies included
in the Orphanet list of rare diseases.13
Papers were selected for full-text screening if they fulfilled any of the
following criteria:
• reviews which described metrics used in literature; OR
• papers comparing two or more different quantity metrics for antibiotic
use/prescribing; OR
• papers which used the quantity metric (one or more) to assess correla-
tion between antibiotic use and selection or propagation of antimicro-
bial resistance; OR
• papers which developed a new (unknown) quantity metric for antibiotic
use/prescribing; OR
• papers concerning (methodological) issues in quantifying antibiotic use/
prescribing.
Papers for which the full text could not be retrieved from any of the libra-
ries of the participating centres (five different catalogues) were also
excluded.
Screening process, data collection and analysis
Special systematic review software (DistillerSRV
R
, Evidence Partners, Ottawa,
Ontario, Canada) was used for literature screening based on defined inclu-
sion and exclusion criteria. Two reviewers (M. S. B., R. M.) independently
screened the titles and abstracts of the records retrieved by the initial
search. Discrepancies between the reviewers were resolved through a dis-
cussion with a third reviewer (V. V.-P.). Three reviewers (M. S. B., R. M., V. V.-
P.) independently extracted relevant data from included articles. A random
selection of 10 papers was used as a pilot test to clarify any ambiguities in
the process of data extraction. From the eligible studies, the following data
were retrieved: study objective; study design (cross-sectional, prospective,
retrospective, literature review); the type of quantitative metric (e.g. vol-
ume, cost); and the definition of metric by numerator/denominator.
All extracted inpatient quantity metrics (IQMs) from the included stud-
ies were grouped into categories based on the numerator. These IQMs
were then presented to the stakeholders in the consensus procedure.
Web site search
The web sites of national and international organizations were also
searched for data reporting antibiotic IQMs published until 29 January
2015. Two reviewers (M. S. B. and R. M.) screened a selection of relevant
web sites. These web sites were selected based on a discussion with all
study authors. The list of searched web sites is presented in Table S2. Data
were extracted and all extracted IQMs from the included web sites were
grouped into categories based on the numerator and presented to the
stakeholders in the consensus procedure.
RAND-modified Delphi procedure
The RAND-modified Delphi procedure consisted of a two-round online sur-
vey addressed to a multidisciplinary expert panel of stakeholders with a
face-to-face meeting held between the two surveys. International stake-
holders were invited by e-mail to participate. The selection process of the
stakeholders is described elsewhere.8 Fifty-two stakeholders amongst four
different groups, aiming at representing all parties involved with antibiotic
use, were invited: medical community (n"15); public health and patients
(n"12); antibiotic research and development (R&D) (n"14); and payers,
policy makers, governments and regulators (n"11). These are detailed in
Table S3. The IQMs extracted from the included studies and web sites were
classified according to the category of the numerator and similar IQMs
were grouped together (e.g. numerator: Treatment courses categorized
together with Treatment period). The list of IQMs was converted into an
internet-based questionnaire (Figure S1) using SurveyMonkeyV
R
(Palo Alto,
CA, USA). Stakeholders assessed the relevance of the extracted IQMs in the
first-round internet-based questionnaire using a nine-point Likert scale
ranging from 1, ‘Clearly not relevant’, to 9, ‘Clearly relevant’, plus a ‘Cannot
assess’ option, and there was a comments box for each IQM. IQMs were
selected if the median score was7 with agreement, held for discussion if
the median score was 7 with disagreement, and rejected if the median
score was ,7. Agreement was defined as 70% of the scores being in the
top tertile (score 7–9). Additionally, stakeholders were asked to select rele-
vant denominators (one or more) for each of the proposed IQM numera-
tors. The stakeholders also had an option to propose new IQMs that had
not been presented in the first online survey.
After the first online survey, a face-to-face consensus meeting with
stakeholders was held to discuss disagreements and to evaluate newly
suggested metrics. During the meeting the stakeholders could accept,
rephrase or reject presented IQMs.
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A detailed overview of the first survey and face-to-face meeting was
submitted to the multidisciplinary stakeholder panel in a second internet-
based survey (data not shown). Stakeholders could accept or reject the
updated set of IQMs and comment on any relevant issues. Finally, IQMs
were accepted if.70% of the respondents agreed with their selection.
Results
Systematic review of the literature and web sites
The flow chart of the review process is shown in Figure 1. The initial
search of the MEDLINE database identified 1152 articles. An addi-
tional 41 articles were identified through cross-referencing
(n"13) and searching of web sites (n"28). By screening the
abstracts, 968 articles and duplicates were excluded. An additional
57 articles were excluded for the following reasons: 29 did not
have full text available and 28 did not meet the inclusion criteria.
The complete search resulted in 168 articles (140 from MEDLINE
and 28 from web sites). Table S4 shows the articles and the follow-
ing characteristics: author, year of publication, country, socioeco-
nomic setting, study design, specific populations and objectives of
the studies included in the review. In addition, summary descrip-
tions of included studies are presented in Table S5. Based on
the numerator, 20 different classes of IQMs were generated
(74 numerator/denominator combinations). The definitions of all
included IQMs are listed in Table 1. The consensus process with
final IQMs is described In Table 2.
Results of the first online-based stakeholder survey
Twenty-three of the 52 stakeholders initially invited (44%) com-
pleted the survey between August and September 2015.
Out of the 20 IQMs presented for assessment through the first
online-based survey questionnaire, ‘Days of therapy (DOT)’, with
all denominators, was selected for the second online survey;
N=1152 publications identified by
MEDLINE searching and screened
for title and abstract
N=41 eligible articles identified
through cross-referencing (n=13)
and web site searching (n=28)
N=968 articles excluded
N=225 full-text articles assessed
for eligibility
N=57 full-text articles excluded:
Not full text available n=29
Not including relevant endpoints n=28
N=168 articles included
Figure 1. The flow chart of the systematic review process of the literature.
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metrics based on the numerators ‘DDDs’, ‘Prescribed daily dose
(PDDs)’, ‘Length of therapy (LOT)’ and ‘Patients exposed to antibi-
otics’ were labelled for discussion, and the 15 remaining IQMs
were excluded. A newly suggested IQM for further assessment
was ‘Antibiotic use should be preferably expressed in at least two
metrics simultaneously’ (Table 2).
Results of the consensus meeting on the IQMs of
antibiotic use
The face-to-face consensus meeting took place on 30 September
2015. Sixteen stakeholders who participated in the first online sur-
vey attended the meeting. All four numerators labelled for discus-
sion from the first round survey (‘DDDs’, ‘PDDs’, ‘LOT’, ‘Patients
exposed to antibiotics’) with denominators within the top two or
three (11 numerator/denominator combinations) and the newly
suggested IQM (‘Antibiotic use should be preferably expressed in
at least two metrics simultaneously’) were selected for the final-
round evaluation (Table 2).
Results of the second online-based stakeholder survey
The second round was completed between December 2015 and
February 2016. Overall response rate was 88% (22 out of 25 invited
stakeholders completed the survey). The result of the consensus
procedure as a final set of 12 IQMs of antibiotic use is shown in
Table 3.
Discussion
This study identified 12 IQMs as appropriate for quantifying antibi-
otic use by a Delphi procedure including a multidisciplinary panel
of international stakeholders (Figure 2). The 12 IQMs represent
only one-sixth of the comprehensive list of 74 IQMs generated
through a systematic review of the literature and relevant web
sites. In addition, new IQMs were added by the panel. The consen-
sus procedure identified the limitations of individual IQMs, and
stakeholders specifically proposed a preference that antibiotic use
be quantified in at least two different metrics simultaneously.
Other authors have stated that, although each IQM individually
measures and describes different aspects of antibiotic prescribing,
Table 1. Definitions of included numerators of inpatient quantity metrics for antibiotic use following the systematic review
Defined daily dose (DDD) An agreed technical statistical unit developed by the WHO Collaborating Centre for Drug
Statistics Methodology; it is the assumed average maintenance dose per day for a drug used
for its main indication in adults.
Hospital-adjusted defined daily
dose (haDDD)
Determined from recommendations in regional or national guidelines on antibiotic use in
hospital.
Prescribed daily dose (PDD) Derived from actually prescribed/administered dose to a patient. It is the average dose pre-
scribed according to a representative sample of prescriptions. The PDD will give the average
daily amount of a drug that is actually prescribed.
Recommended daily dose (RDD) Similar to DDD but the daily dose is defined by local guidelines; usually varies according to the
weight of the patient.
Doses/units Expressed in mg/kg/day or g/patient/day or g or mg.
Packages The number or vials, bottles, pills/tablets, infusion bags, packages.
Prescriptions The number or percentage of prescriptions containing antibiotics.
Days of therapy (DOT)a The number of days that a patient receives antibiotics regardless of the dose. When a patient
receives more than one antibiotic, more than one DOT may be counted. Synonym: antibiotic
days or antimicrobial days.
Agent days The number of days that a patient received a particular agent; defined by subtracting the date
of the first dose of the antibiotic course from the date of the last dose.
Length of therapy (LOT) or duration of
treatment (DOT) or days of treatment (DOT)
The number of days that a patient receives systemic antimicrobial agents, irrespective of the
number of different antibiotics. Therefore, LOT will be lower than or equal to days of therapy
(DOT) because the DOT is calculated for each antibiotic.
Treatment courses Period during which the same agent (regardless of dose or route) was administered to the
same patient on consecutive days. One patient may be given more than one treatment
course at a time. Synonym: treatment period.
Length of stay (LOS) or antibiotic-related
length of stay (ALOS)
Defined as the length of an inpatient episode of care, calculated from the day of admission to
the day of discharge, and based on the number of nights spent in hospital. Patients admitted
and discharged on the same day have a length of stay of ,1 day.
Patients Defined as the number or percentage of patients receiving one or more antibiotics or patients
exposed to antibiotics.
Drug utilization index (DU) The number of drugs accounting for 75%/90%/100% of total drug use.
Antibiotic costs Defined as the total amount or percentage of costs of antibiotic per total drug costs.
Drug cost index 90% (DC 90%) The costs of drugs accounting for 90% of total drug costs.
aIn the literature, the acronym DOT is also used for duration of treatment and days of treatment, which are used as synonyms of length of therapy.
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Table 2. The consensus process of selecting the inpatient quantity metrics for antibiotic use
Proposed numerator/denominators
Conclusion after the
first survey
Conclusion after the
consensus meetinga
Final conclusion after
the second survey
I. Defined daily doses (DDDs)b
No denominator Labelled for discussion Selected Selected
100(0) PDs/BDs/OBDsc 100(0) PDs/BDs/OBDs (61%) IQM 1
Admissions Admissions (44%) IQM 2
100 BDs per CMId 100 BDs per CMI (35%) IQM 3
1000 inhabitants per day
Discharges
Age-adjusted comorbidity score, 100 PDs/age
adjusted comorbidity score
FCEse
Number of treatment days
Patients
100 BDs/f
100 admissions per CMI
II. Hospital-adjusted DDDs (haDDDs)
No denominator Rejected – –
100 PDs
100 discharges
III. Prescribed daily dose (PDDs)
No denominator Labelled for discussion Selected Selected
100 PDs 100 PDs (70%) IQM 4
Admissions Admissions (30%)
DDDs DDDs (30%)
RDDs
V. Recommended daily doses (RDDs)
No denominator Rejected – –
PDs
V. Doses/unit (mg/kg/day or g/patient/day or g or mg)
No denominator Rejected – –
Days of therapy
VI. Packages
No denominator Rejected – –
VII. Prescriptions
No denominator Rejected – –
Admissions
VIII. Average number of drugs (antibiotics) per prescription
No denominator Rejected – –
IX. Days of therapy (DOT) (synonym: antibiotic days or antimicrobial days)
No denominator Selected Selected Selected
PDs PDs (52%) IQM 5
Patients Patients (30%) IQM 6
Admissions Admissions (30%) IQM 7
Discharges
Length of therapy (LOT)
Expected days of therapy (DOT)
X. Antibiotic days or antimicrobial days
No denominator Rejected – –
Admissions
PDs
1000 FCEs
XI. Agent days
No denominator Rejected – –
Admissions
1000 FCEs
Continued
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Table 2. Continued
Proposed numerator/denominators
Conclusion after the
first survey
Conclusion after the
consensus meetinga
Final conclusion after
the second survey
XII. Length of therapy (LOT)
No denominator Labelled for discussion Selected Selected
PDs PDs (44%)
Admissions Admissions (39%) IQM 8
Patients Patients (30%) IQM 9
Discharges
1000 FCEs
XIII. Treatment courses (synonym: treatment period)
No denominator Rejected – –
Admissions
PDs
1000 FCEs
Total number of treatment courses
XIV. Percentage of classes of antimicrobials that accounted for more than a certain percentage (10% or 50%) of treatment courses
– Rejected – –
XV. Number or percentage of different antibiotics used/prescribed
No denominator Rejected – –
Patient
Days of treatment
1000 resident care days
Hospital
XVI. Length of stay (LOS) or antibiotic-related length of stay (ALOS)
No denominator Rejected – –
PDs
XVII. Patients
No denominator Labelled for discussion Selected Selected
All patients All patients (26%) IQM 10
Admissions Admissions (22%) IQM 11
XVIII. Drug utilization index (DU) DU 75%, DU 90%, DU 100%
No denominator Rejected – –
XIX. Antibiotic costs
No denominator Rejected – –
PDs
Overall cost of treatment
Treatment days (antibiotic days)
Admissions
DDDs
FCEs
Dose
XX. Drug cost index 90% (DC 90%)
No denominator Rejected – –
XXI. Antibiotic use should be preferably expressed in at least two
metrics simultaneously
– Newly suggested Selected:
IQM 12
aTop two/three denominators ranked by the stakeholders.
bBold text shows inpatient quantity metrics that were selected as a result of the consensus procedure.
c100 or 1000 patient-days (PDs)/bed-days (BDs)/occupied bed-days (OBDs).
dCMI, case mix index. This is a relative value assigned to a diagnosis-related group of patients in a medical care environment.
eFCE, finished consultant episode. This is an NHS term for a consultant episode that has ended due to discharge, transfer or death.
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the actual antibiotic use can be more precisely evaluated in combi-
nation with at least one additional IQM.14,15 The three IQMs with
DDDs as a numerator selected in the consensus procedure repre-
sent widely used metrics that can relatively easily be obtained and
calculated and can thus be used to measure the use of different
antibiotics, across different centres and countries.16 However,
although the Infectious Diseases Society of America released a
guideline in which DDDs is recommended for benchmarking pur-
poses, there are still too many IQMs on antibiotic use present in the
published literature that preclude a valid comparison of data
within and between institutions.5,17 On the other hand, using only
DDDs for comparison purposes does not always offer a clear, real-
istic picture of antibiotic use in practice.18 DDDs as a metric is rele-
vant only for adult populations.19 Some of the factors that may
influence variations in antibiotic use measured in DDDs are reduc-
tion in administered daily dose (e.g. renal impairment, weight-
based dosing in children), different dosing recommendations in
different countries and route of administration (oral, paren-
teral).20,21 Hence, as pointed out by others, in order to enable more
informative benchmarking, other IQMs, including PDDs, DOT, LOT
and exposed patients, all as numerators, may yield a more valid
description of antibiotic exposure than DDDs alone.21–24 Polk
et al.21 and Dalton et al.25 analysed similarities and differences
between DDDs and DOT. For example, when the administered dos-
age was less than the DDDs, such as for ceftriaxone in the study by
MacDougall and Polk,26 estimates of use based on DDDs/1000
patient-days (PDs) were significantly lower than those based on
DOT/1000 PDs. Addition of another unit of measure, such as DOT,
might also be helpful to meaningfully interpret data on the impact
of antibiotic use, since the effects on the microbiota might depend
more on total duration of treatment than on total daily dose.20
Although the recommendation to provide two IQMs simultane-
ously is not a metric in itself, we reported it as the 12th IQM accord-
ing to the analytical process involved in this study. In order to
accurately report antibiotic use in the paediatric setting, the 12th
metric could be particularly helpful.27 Reporting the quantity of
antibiotic use by at least two different IQMs simultaneously gives a
reporter an option to use a DDD-based metric as a measure of
overall use per unit population accompanied by any of the other
proposed IQMs that would best fit the investigator’s requirements
and the aim of the reported data, frequently describing an individ-
ual, patient-level pattern of antibiotic use.
Stakeholders involved in this survey also chose case-mix index
(CMI) as a denominator with DDDs as one of the 12 proposed
IQMs. CMI is used as a risk adjustment for antibiotic utilization
across different institutions.28–30 Considering the confounding
effect of different wards and intra- and inter-institutional patient
characteristics, the proposed IQM, DDDs/100 bed-days (BDs) per
CMI may help to overcome this barrier and render the measure-
ment of antibiotic use more realistic. Haug et al.31 and Rajmokan
et al.32 emphasized that there is no consistent definition and index
of CMI. Thus, we recommend that a definition of CMI should be
specified in studies involving this indicator.28,29
Morris et al.24 used a somewhat similar methodological
approach to assess IQMs that are used to evaluate the impact of
antimicrobial stewardship programmes and serve for public
reporting. Potential for selection bias in the measures presented
for evaluation to the expert panel and the lack of detailed reporting
regarding all steps of the systematic review process present impor-
tant limitations of their study.24 There are also a few other studies
that described advantages and disadvantages of commonly used
IQMs for antibiotic use that were highlighted by the participants in
our consensus procedure.15,33,34 Many factors are recognized as
influencing reliable reporting and comparison of antibiotic use
worldwide. Different electronic prescribing modules use different
filters for data extraction; pharmacy sales data aggregated over
short registration intervals may significantly differ from ward stock
accounting for the same period; risk adjustment of antibiotic use
for patient mix and severity of illness is important.23,31,32,35,36
Metrics describing costs and other low-informative metrics
(e.g. DDDs/day; minimum marketed dose; average number of anti-
biotics per prescription) generated through a systematic review
process were both regarded as non-relevant by stakeholder
assessment and previous studies.3,24,37
Definitions of involved IQMs for antibiotic use and data sources
have an important effect on published results concerning the vol-
ume of antibiotic use.25,38 Consistency across definitions and
quantity measures used in surveys should be synchronized world-
wide and we promote this by providing a complete list of defini-
tions of IQM numerators used internationally and emphasizing
specific terms for IQMs. We propose to use the abbreviation ‘DOT’
only for days of therapy, excluding other terms abbreviated to DOT
in the literature (Table 1). Another proposal that has arisen from
this consensus process is that denominators should be clearly
defined. It should be clearly stated whether the calculation of
number of admissions and discharges between different depart-
ments within one hospital include only 1 day of hospitalization.39
Also, it is important to state whether patient-days are calculated
based on calendar days or passages of midnight. Data sources
(e.g. dispensing pharmacies data), including also specific pro-
viders of data (e.g. manufacturers, wholesalers, pharmacies)
should be clearly specified to achieve more realistic insight.25
Kuster et al.39 have made recommendations for reporting
methodological information for clear standardized reporting on
hospital antibiotic use.
Table 3. The final set of 12 evidence-based and consensually validated
quantity metrics for antibiotic use in the inpatient setting
Inpatient quantity metric (IQM)
IQM 1: Defined daily doses (DDDs) per 100(0) PDs/BDs/OBDsa
IQM 2: Defined daily doses (DDDs) per admission
IQM 3: Defined daily doses (DDDs) per (100 bed-days per CMIb)
IQM 4: Prescribed daily doses (PDDs) per 100 PDs
IQM 5: Days of therapy (DOT) per PD
IQM 6: Days of therapy (DOT) per patient
IQM 7: Days of therapy (DOT) per admission
IQM 8: Length of therapy (LOT) per admission
IQM 9: Length of therapy (LOT) per patient
IQM 10: Patients exposed to antibiotics per all patients
IQM 11: Patients exposed to antibiotics per admission
IQM 12: Antibiotic use should be preferably expressed in at least two
metrics simultaneously
a100(0) patient-days (PD)/bed-days (BDs)/occupied bed-days (OBDs).
bCMI, case mix index. This is a relative value assigned to a diagnosis-
related group of patients in a medical care environment.
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One of the strengths of this study is our methodological
approach involving a comprehensive four step RAND-modified
Delphi procedure (systematic review, first online survey, consensus
meeting and second online survey) in which international multidis-
ciplinary representatives of all concerned stakeholders participated.
Both online surveys had a higher response rate (44% and 88%)
than what is observed on average.40–42 Both online surveys included
a wide range of stakeholders from the medical community, from
patients and global public health, from the pharmaceutical industry,
and from payers, policy makers, government and regulators. One
limitation is that the systematic review process was limited to only
one database (MEDLINE), although it was accompanied by a cita-
tion-tracking search and the review of 26 relevant web sites. The
web site search included the most relevant ones, but not all. One
could interpret it as a limitation of this study, but the web site search
should rather be seen as complementary to the systematic litera-
ture review. It was performed to make sure no metrics were missed
in the literature. Initial arbitrary selection of stakeholders could be
considered a limitation of this study, but all groups were well repre-
sented. The recommendation to report antibiotic use with at least
two different quantity metrics does not indicate which ones are pre-
ferred; this could be a strength and a limitation simultaneously.
Conclusions
Standardization of surveillance methods, including currently used
IQMs, is crucial in order to improve stewardship measures and out-
comes, including antibiotic resistance.34,43,44 Based on a compre-
hensive approach, a set of 12 IQMs on antibiotic use was
generated that may serve for more accurate benchmarking prac-
tice. The last IQM, the recommendation ‘Antibiotic use should be
preferably expressed in at least two metrics simultaneously’, con-
stitutes a valuable new metric. The set of final metrics is a first step
towards harmonized, internationally accepted reporting on the
quantity of antibiotic use.
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